GlassScriptPhysician profile
Yelena Rosenberg
NPI 1598763187
$2,940.87
in general payments reported to CMS, 2019-2025
21 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $542 · 2021: $621 · 2022: $269 · 2023: $200 · 2024: $312 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.73 | 2019-2025 | Farxiga |
| Amgen INC. | $635.00 | 2019-2025 | Repatha, Krystexxa |
| Chiesi USA, INC. | $260.00 | 2024-2025 | Mycapssa |
| Opko Pharmaceuticals, LLC | $202.78 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $168.26 | 2019-2025 | Jynarque |
| Esperion Therapeutics, INC. | $125.00 | 2024 | Nexlizet, Nexletol |
| Ardelyx, INC. | $121.84 | 2025 | Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $107.41 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $88.86 | 2021-2024 | Velphoro |
| Akebia Therapeutics INC | $60.84 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $57.36 | 2022-2023 | Acthar |
| Smith+Nephew, INC. | $42.79 | 2022 | |
| Fresenius USA Manufacturing, INC. | $40.89 | 2025 | |
| Vifor Pharma, INC. | $40.82 | 2021-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $39.27 | 2021-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.21 | 2023-2025 | Ultomiris |
| Horizon Therapeutics Plc | $32.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $27.75 | 2021 | |
| Renalytix Ai, INC. | $22.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Enterprises LLC | $20.96 | 2019 | |
| Aurinia Pharma U.S., INC. | $20.91 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.